Tobira Therapeutics Inc. Initiates Phase IIb Trial of Cenicriviroc, a Novel CCR5/CCR2 Antagonist for the Treatment of HIV Infection
6/22/2011 8:48:22 AM
MANALAPAN, N.J.--(BUSINESS WIRE)--Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652). The multi-center, double-blind, double-dummy, 48-week comparative study is designed to evaluate the efficacy, safety and tolerability of cenicriviroc in 150 HIV-1-infected, antiretroviral treatment-naïve patients with only CCR5-tropic virus. The trial is actively enrolling patients in more than 50 sites across the United States and Puerto Rico.
comments powered by